CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstra

Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors which most often show longer survival in a proportion of patients with a higher level of tumor cell PD-L1 expression



Combination therapy could boost patient outcomes



CEL-SCI has filed a patent for the use of Multikine in tumor expressing low levels of PD-L1

Related Keywords

United States , Montreal , Quebec , Canada , Virginia , Maryland , Baltimore , Vienna , Wien , Austria , United Kingdom , American , Philip Lavin , Exchange Commission , Securities Exchange , International Conference On Head , European Union , Neck Cancer Society , Drug Administration , American Head , Annual International Conference , Neck Cancer , Leukocyte Interleukin Injection , Programmed Death Ligand , Leukocyte Interleukin , Orphan Drug , Securities Act , Securities Exchange Act , Markets ,